Australia's most trusted
source of pharma news
Thursday, 03 April 2025
Posted 1 April 2025 AM
The TGA has kicked off 2025 with a bang, approving 17 drug expansions in just two months – almost double the amount compared to the same time last year.
Some big drugs have scored multiple new indications with MSD’s PD-1 inhibitor Keytruda, which earned a massive $96.85 million in pre-rebate PBS benefits in January, topping the list.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.